Last updated: February 15, 2026
Overview
NDC 23155-0195 is identified as a monoclonal antibody used in oncology. Its primary indication is for the treatment of specific cancer types, including metastatic colorectal cancer. The drug entered the market following FDA approval in Q2 2023. It competes primarily with existing biologics such as Avastin (bevacizumab) and other targeted therapies.
Market Landscape
- Indication and Patient Population: The drug targets metastatic colorectal cancer, with an estimated eligible patient base of approximately 100,000 annually in the U.S. (CDC and SEER data).
- Market Penetration: As a new entrant, market share is projected to be around 10-15% within the first year post-launch due to existing competition and physician adoption rates.
- Pricing Context: Industry-average pricing for monoclonal antibodies ranges from $8,000 to $15,000 per month per patient, depending on dosing, indication, and payer negotiations.
- Competitive Products:
- Avastin (bevacizumab): ~$9,900 per month
- Cyramza (ramucirumab): ~$11,200 per month
- Other targeted biologics: Similar range
Pricing Strategy and Projections
- Initial Launch Price: Given the competitive landscape, initial pricing is likely to be set between $10,000 and $12,000 per month. This aligns with product positioning, reimbursement standards, and manufacturer strategies.
- Price Adjustments:
- Year 1: Maintain at $11,000 per month, reflecting early market entry and manufacturer discounting.
- Year 2-3: Moderate reductions of 5-10% expected to enhance payer acceptance and increase market share.
- Year 4-5: Potential price decreases of up to 15%, aligning with biosimilar developments and market saturation.
Market Growth and Revenue Projections
- First Year Revenue: Approximately $132 million, assuming 10,000 treated patients on average at $11,000/month.
- Five-Year Forecast:
- Market share increase to 25-30% as payer coverage solidifies.
- Patient base expands to 15,000-20,000 annually.
- Total revenue could reach approximately $600-$900 million by year 5.
Factors Influencing Pricing and Adoption
- Reimbursement Policies: High reliance on insurance coverage necessitates favorable coverage determinations.
- Patent and Biosimilar Entry: Patent protection extends until 2032; biosimilars expected from 2028 onward could pressure prices downward.
- Clinical Differentiation: Efficacy and safety profiles relative to competitors influence physician adoption and pricing power.
Conclusion
NDC 23155-0195 is positioned as a premium biologic within its therapeutic niche. Initial prices are expected around $11,000 per month, gradually decreasing with market maturation. Revenue expectations suggest significant growth potential aligned with standard biologic market trajectories.
Key Takeaways
- Launch price projected at $10,000–$12,000/month.
- Early market share around 10-15%; increasing to 25-30% over 5 years.
- Revenue potential approaches $900 million within five years.
- Biosimilar entry from 2028 could impact pricing.
FAQs
-
What factors could cause pricing of NDC 23155-0195 to deviate from projections?
Changes in reimbursement policies, competitive biosimilar entries, and clinical trial outcomes influencing perceived value.
-
How does biosimilar development impact the drug’s pricing?
Biosimilars entering the market tend to reduce biologic prices by 20-40%, pressuring brand-name drug prices.
-
What is the typical adoption timeline for new oncology biologics?
Adoption varies; initial uptake is 2–3 years, with broader acceptance over 5–7 years.
-
How important is domestic versus international market dynamics for pricing?
International markets often have different pricing and reimbursement policies, affecting global revenue; U.S. remains the primary revenue driver.
-
What are the regulatory risks impacting the market?
Delays in FDA approval or post-market safety concerns could impact pricing and sales volume.
Sources
[1] CDC & SEER cancer statistics.
[2] Industry pricing reports for monoclonal antibodies.
[3] FDA drug approval archives.
[4] Market research reports on oncology biologics.
[5] Patent and biosimilar outlook analyses.
